Key result
Mineralocorticoid receptor antagonists reduce cardiovascular death and heart failure hospitalization in patients with cardiovascular and heart failure risk factors.
Why the study?
Do mineralocorticoid receptor antagonists prevent atrial fibrillation in patients with and without heart failure?
Do mineralocorticoid receptor antagonists prevent atrial fibrillation in patients with and without heart failure?
Answers are grounded in this paper and cite their sources.
This editorial discusses the potential of mineralocorticoid receptor antagonists to prevent atrial fibrillation and reduce cardiovascular death and heart failure hospitalization.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zurkan et al. (2024) studied this question. Mineralocorticoid receptor antagonists reduce cardiovascular death and heart failure hospitalization in patients with cardiovascular and heart failure risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: